

Neuroendocrine Carcinoma Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/ND4B4CFE891DEN.html>

Date: February 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: ND4B4CFE891DEN

Abstracts

This report contains market size and forecasts of Neuroendocrine Carcinoma Treatment in Global, including the following market information:

Global Neuroendocrine Carcinoma Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Neuroendocrine Carcinoma Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Chemotherapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neuroendocrine Carcinoma Treatment include Pfizer, Novartis, Chiasma, Ipsen, Abbvie, Bausch Health, Jubilant, Teva and F.Hoffmann-La Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuroendocrine Carcinoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neuroendocrine Carcinoma Treatment Market, by Type, 2017-2022, 2023-2028
(\$ millions)

Global Neuroendocrine Carcinoma Treatment Market Segment Percentages, by Type,
2021 (%)

Chemotherapy

Somatostatin Analogs

Targeted Therapy

Global Neuroendocrine Carcinoma Treatment Market, by Application, 2017-2022,
2023-2028 (\$ millions)

Global Neuroendocrine Carcinoma Treatment Market Segment Percentages, by
Application, 2021 (%)

Hospital

Clinics

Oncology Centres

Ambulatory Surgery Centres

Global Neuroendocrine Carcinoma Treatment Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Neuroendocrine Carcinoma Treatment Market Segment Percentages, By Region
and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neuroendocrine Carcinoma Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Neuroendocrine Carcinoma Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Novartis

Chiasma

Ipsen

Abbvie

Bausch Health

Jubilant

Teva

F.Hoffmann-La Roche

Advanced Accelerator

Mateon

Lexicon

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Neuroendocrine Carcinoma Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Neuroendocrine Carcinoma Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROENDOCRINE CARCINOMA TREATMENT OVERALL MARKET SIZE

- 2.1 Global Neuroendocrine Carcinoma Treatment Market Size: 2021 VS 2028
- 2.2 Global Neuroendocrine Carcinoma Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Neuroendocrine Carcinoma Treatment Players in Global Market
- 3.2 Top Global Neuroendocrine Carcinoma Treatment Companies Ranked by Revenue
- 3.3 Global Neuroendocrine Carcinoma Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Neuroendocrine Carcinoma Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Neuroendocrine Carcinoma Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Neuroendocrine Carcinoma Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Neuroendocrine Carcinoma Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Neuroendocrine Carcinoma Treatment

Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Neuroendocrine Carcinoma Treatment Market Size Markets, 2021 & 2028

4.1.2 Chemotherapy

4.1.3 Somatostatin Analogs

4.1.4 Targeted Therapy

4.2 By Type - Global Neuroendocrine Carcinoma Treatment Revenue & Forecasts

4.2.1 By Type - Global Neuroendocrine Carcinoma Treatment Revenue, 2017-2022

4.2.2 By Type - Global Neuroendocrine Carcinoma Treatment Revenue, 2023-2028

4.2.3 By Type - Global Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Neuroendocrine Carcinoma Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinics

5.1.4 Oncology Centres

5.1.5 Ambulatory Surgery Centres

5.2 By Application - Global Neuroendocrine Carcinoma Treatment Revenue & Forecasts

5.2.1 By Application - Global Neuroendocrine Carcinoma Treatment Revenue, 2017-2022

5.2.2 By Application - Global Neuroendocrine Carcinoma Treatment Revenue, 2023-2028

5.2.3 By Application - Global Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neuroendocrine Carcinoma Treatment Market Size, 2021 & 2028

6.2 By Region - Global Neuroendocrine Carcinoma Treatment Revenue & Forecasts

- 6.2.1 By Region - Global Neuroendocrine Carcinoma Treatment Revenue, 2017-2022
- 6.2.2 By Region - Global Neuroendocrine Carcinoma Treatment Revenue, 2023-2028
- 6.2.3 By Region - Global Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028
- 6.3 North America
 - 6.3.1 By Country - North America Neuroendocrine Carcinoma Treatment Revenue, 2017-2028
 - 6.3.2 US Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.3.3 Canada Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.3.4 Mexico Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
- 6.4 Europe
 - 6.4.1 By Country - Europe Neuroendocrine Carcinoma Treatment Revenue, 2017-2028
 - 6.4.2 Germany Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.4.3 France Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.4.4 U.K. Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.4.5 Italy Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.4.6 Russia Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.4.7 Nordic Countries Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.4.8 Benelux Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
- 6.5 Asia
 - 6.5.1 By Region - Asia Neuroendocrine Carcinoma Treatment Revenue, 2017-2028
 - 6.5.2 China Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.5.3 Japan Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.5.4 South Korea Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.5.5 Southeast Asia Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.5.6 India Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
- 6.6 South America
 - 6.6.1 By Country - South America Neuroendocrine Carcinoma Treatment Revenue, 2017-2028
 - 6.6.2 Brazil Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.6.3 Argentina Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
- 6.7 Middle East & Africa
 - 6.7.1 By Country - Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue, 2017-2028
 - 6.7.2 Turkey Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.7.3 Israel Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.7.4 Saudi Arabia Neuroendocrine Carcinoma Treatment Market Size, 2017-2028
 - 6.7.5 UAE Neuroendocrine Carcinoma Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Neuroendocrine Carcinoma Treatment Major Product Offerings

7.1.4 Pfizer Neuroendocrine Carcinoma Treatment Revenue in Global Market
(2017-2022)

7.1.5 Pfizer Key News

7.2 Novartis

7.2.1 Novartis Corporate Summary

7.2.2 Novartis Business Overview

7.2.3 Novartis Neuroendocrine Carcinoma Treatment Major Product Offerings

7.2.4 Novartis Neuroendocrine Carcinoma Treatment Revenue in Global Market
(2017-2022)

7.2.5 Novartis Key News

7.3 Chiasma

7.3.1 Chiasma Corporate Summary

7.3.2 Chiasma Business Overview

7.3.3 Chiasma Neuroendocrine Carcinoma Treatment Major Product Offerings

7.3.4 Chiasma Neuroendocrine Carcinoma Treatment Revenue in Global Market
(2017-2022)

7.3.5 Chiasma Key News

7.4 Ipsen

7.4.1 Ipsen Corporate Summary

7.4.2 Ipsen Business Overview

7.4.3 Ipsen Neuroendocrine Carcinoma Treatment Major Product Offerings

7.4.4 Ipsen Neuroendocrine Carcinoma Treatment Revenue in Global Market
(2017-2022)

7.4.5 Ipsen Key News

7.5 Abbvie

7.5.1 Abbvie Corporate Summary

7.5.2 Abbvie Business Overview

7.5.3 Abbvie Neuroendocrine Carcinoma Treatment Major Product Offerings

7.5.4 Abbvie Neuroendocrine Carcinoma Treatment Revenue in Global Market
(2017-2022)

7.5.5 Abbvie Key News

7.6 Bausch Health

- 7.6.1 Bausch Health Corporate Summary
- 7.6.2 Bausch Health Business Overview
- 7.6.3 Bausch Health Neuroendocrine Carcinoma Treatment Major Product Offerings
- 7.6.4 Bausch Health Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
- 7.6.5 Bausch Health Key News
- 7.7 Jubilant
 - 7.7.1 Jubilant Corporate Summary
 - 7.7.2 Jubilant Business Overview
 - 7.7.3 Jubilant Neuroendocrine Carcinoma Treatment Major Product Offerings
 - 7.7.4 Jubilant Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
 - 7.7.5 Jubilant Key News
- 7.8 Teva
 - 7.8.1 Teva Corporate Summary
 - 7.8.2 Teva Business Overview
 - 7.8.3 Teva Neuroendocrine Carcinoma Treatment Major Product Offerings
 - 7.8.4 Teva Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
 - 7.8.5 Teva Key News
- 7.9 F.Hoffmann-La Roche
 - 7.9.1 F.Hoffmann-La Roche Corporate Summary
 - 7.9.2 F.Hoffmann-La Roche Business Overview
 - 7.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Treatment Major Product Offerings
 - 7.9.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
 - 7.9.5 F.Hoffmann-La Roche Key News
- 7.10 Advanced Accelerator
 - 7.10.1 Advanced Accelerator Corporate Summary
 - 7.10.2 Advanced Accelerator Business Overview
 - 7.10.3 Advanced Accelerator Neuroendocrine Carcinoma Treatment Major Product Offerings
 - 7.10.4 Advanced Accelerator Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
 - 7.10.5 Advanced Accelerator Key News
- 7.11 Mateon
 - 7.11.1 Mateon Corporate Summary
 - 7.11.2 Mateon Business Overview

- 7.11.3 Mateon Neuroendocrine Carcinoma Treatment Major Product Offerings
- 7.11.4 Mateon Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
- 7.11.5 Mateon Key News
- 7.12 Lexicon
 - 7.12.1 Lexicon Corporate Summary
 - 7.12.2 Lexicon Business Overview
 - 7.12.3 Lexicon Neuroendocrine Carcinoma Treatment Major Product Offerings
 - 7.12.4 Lexicon Neuroendocrine Carcinoma Treatment Revenue in Global Market (2017-2022)
 - 7.12.5 Lexicon Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neuroendocrine Carcinoma Treatment Market Opportunities & Trends in Global Market

Table 2. Neuroendocrine Carcinoma Treatment Market Drivers in Global Market

Table 3. Neuroendocrine Carcinoma Treatment Market Restraints in Global Market

Table 4. Key Players of Neuroendocrine Carcinoma Treatment in Global Market

Table 5. Top Neuroendocrine Carcinoma Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Neuroendocrine Carcinoma Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Neuroendocrine Carcinoma Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Neuroendocrine Carcinoma Treatment Product Type

Table 9. List of Global Tier 1 Neuroendocrine Carcinoma Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Neuroendocrine Carcinoma Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Neuroendocrine Carcinoma Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Neuroendocrine Carcinoma Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Neuroendocrine Carcinoma Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Neuroendocrine Carcinoma Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Neuroendocrine Carcinoma Treatment Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Neuroendocrine Carcinoma Treatment Product Offerings

Table 32. Pfizer Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Novartis Corporate Summary

Table 34. Novartis Neuroendocrine Carcinoma Treatment Product Offerings

Table 35. Novartis Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Chiasma Corporate Summary

Table 37. Chiasma Neuroendocrine Carcinoma Treatment Product Offerings

Table 38. Chiasma Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Ipsen Corporate Summary

Table 40. Ipsen Neuroendocrine Carcinoma Treatment Product Offerings

Table 41. Ipsen Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Abbvie Corporate Summary

Table 43. Abbvie Neuroendocrine Carcinoma Treatment Product Offerings

Table 44. Abbvie Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Bausch Health Corporate Summary

Table 46. Bausch Health Neuroendocrine Carcinoma Treatment Product Offerings

Table 47. Bausch Health Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Jubilant Corporate Summary

Table 49. Jubilant Neuroendocrine Carcinoma Treatment Product Offerings

Table 50. Jubilant Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Teva Corporate Summary

Table 52. Teva Neuroendocrine Carcinoma Treatment Product Offerings

Table 53. Teva Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. F.Hoffmann-La Roche Corporate Summary

Table 55. F.Hoffmann-La Roche Neuroendocrine Carcinoma Treatment Product Offerings

Table 56. F.Hoffmann-La Roche Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Advanced Accelerator Corporate Summary

Table 58. Advanced Accelerator Neuroendocrine Carcinoma Treatment Product Offerings

Table 59. Advanced Accelerator Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Mateon Corporate Summary

Table 61. Mateon Neuroendocrine Carcinoma Treatment Product Offerings

Table 62. Mateon Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. Lexicon Corporate Summary

Table 64. Lexicon Neuroendocrine Carcinoma Treatment Product Offerings

Table 65. Lexicon Neuroendocrine Carcinoma Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Neuroendocrine Carcinoma Treatment Segment by Type in 2021
- Figure 2. Neuroendocrine Carcinoma Treatment Segment by Application in 2021
- Figure 3. Global Neuroendocrine Carcinoma Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Neuroendocrine Carcinoma Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Neuroendocrine Carcinoma Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Neuroendocrine Carcinoma Treatment Revenue in 2021
- Figure 8. By Type - Global Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028
- Figure 12. US Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn),

2017-2028

Figure 23. By Region - Asia Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028

Figure 24. China Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Neuroendocrine Carcinoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Novartis Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Chiasma Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Ipsen Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Abbvie Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Bausch Health Neuroendocrine Carcinoma Treatment Revenue Year Over

Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Jubilant Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Teva Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. F.Hoffmann-La Roche Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Advanced Accelerator Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Mateon Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Lexicon Neuroendocrine Carcinoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Neuroendocrine Carcinoma Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/ND4B4CFE891DEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ND4B4CFE891DEN.html>